First Tracks Biotherapeutics, Inc.
BioSniper AI · TRAX
First Tracks Biotherapeutics, Inc. (TRAX) is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics, with lead candidates ANB033 for celiac disease and eosinophilic esophagitis and ANB101 for other inflammatory conditions.
Key risk: No product revenue
Spotter reads the filings and answers with citations.
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Tracking 3 pipeline candidates for First Tracks Biotherapeutics, Inc. · Updated within the last hour.
Similar companies
First Tracks Biotherapeutics, Inc. (TRAX) is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics, with lead candidates ANB033 for celiac disease and eosinophilic esophagitis and ANB101 for other inflammatory conditions.
- Clinical-stage company developing antibodies for autoimmune and inflammatory diseases [sec · filed 2026-05-08].
- Lead candidates: ANB033 (Phase 1b in CeD and EoE) and ANB101 (Phase 1a) [sec · filed 2026-05-08].
- Cash & equivalents of $248.5M as of 2026-03-31 [sec].
What works
- The company retains rights in key commercial markets, aiming to become a fully integrated development and commercial organization [sec · filed 2026-05-08].
- Strong cash position of $248.5M as of 2026-03-31 [sec] supports ongoing clinical trials and development through near-term milestones.
- Focus on large, underserved patient populations in gastroenterology, rheumatology, dermatology, and respiratory [sec · filed 2026-05-08].
- Strategy includes generating translational data to differentiate molecules from competitors [sec · filed 2026-05-08].
What to weigh
- No approved products or revenue from product sales; expects to incur significant operating losses for the foreseeable future [sec · filed 2026-05-08].
- History of operational losses and uncertainty about achieving profitability [sec · filed 2026-05-08].
- Product candidates are in early clinical stages and may fail at any point due to safety or efficacy issues [sec · filed 2026-05-08].
- Will require additional capital to fund operations, which may not be available on acceptable terms [sec · filed 2026-05-08].
From the filings
Quoted directly from source documents.
Company is clinical-stage with focus on immunology
“We are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics.”
SEC filings · May 8, 2026
No operating revenue and history of losses
“We have no operating revenue and a history of operational losses and may not achieve or sustain profitability.”
SEC filings · May 8, 2026
Risks & what to watch (4)›
Key risks
- No product revenue — No approved products or revenue from sales, with ongoing reliance on external financing [sec · filed 2026-05-08].
- Clinical failure risk — Product candidates may fail at any stage due to safety, efficacy, or regulatory hurdles [sec · filed 2026-05-08].
- Additional capital needed — Expected to require further financing, which may not be available on acceptable terms [sec · filed 2026-05-08].
- Competitive differentiation — Must demonstrate differentiation from in-class competitors and standard of care [sec · filed 2026-05-08].
What to watch
- Enrollment and data from Phase 1b trial of ANB033 in celiac disease and eosinophilic esophagitis [sec · filed 2026-05-08].
- Phase 1a trial initiation and results for ANB101 [sec · filed 2026-05-08].
- Impacts of tariffs and non-tariff barriers on operations [sec · filed 2026-05-08].
- Any partnership or collaboration deals to fund development [sec · filed 2026-05-08].
Sources: SEC filings · Generated July 14, 2026 · How we verify sources →
Unlock the full First Tracks Biotherapeutics, Inc. dossier
Sign in free to see catalysts, full pipeline, financials, FDA decisions, news, and run live AI deep-dives.
Free account includes:
- Full pipeline, catalysts, financials & FDA decisions for First Tracks Biotherapeutics, Inc.
- 200 free AI credits / month to run live Spotter deep-dives
- Watchlist, news alerts & the biotech event calendar
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
26.3 months
D/E 0.13
No tracked pipeline phase
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for First Tracks Biotherapeutics, Inc.?
First Tracks Biotherapeutics, Inc. (TRAX) is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics, with lead candidates ANB033 for celiac disease and eosinophilic esophagitis and ANB101 for other inflammatory conditions.
Who is the CEO of First Tracks Biotherapeutics, Inc.?
Mr. Daniel R. Faga is the chief executive officer of First Tracks Biotherapeutics, Inc. (TRAX).
Where is First Tracks Biotherapeutics, Inc. headquartered?
First Tracks Biotherapeutics, Inc. (TRAX) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on First Tracks Biotherapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.